FDA Approves XDEMVY 0.25% for the Treatment of Demodex Blepharitis

IRVINE, Calif.—Tarsus Pharmaceuticals, Inc. announced yesterday that the U.S. Food and Drug Administration (FDA) approved XDEMVY (lotilaner ophthalmic solution) 0.25% for the treatment of Demodex blepharitis.